Does Rallies show 13F holders for AURA?

Yes. Rallies tracks hedge fund and 13F ownership data for AURA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is AURA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AURA. It does not provide personalized investment advice.

AURA (Aura Biosciences, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Aura Biosciences, Inc. Common Stock (AURA) is a publicly traded Healthcare sector company. As of May 21, 2026, AURA trades at $8.00 with a market cap of $772.30M and a P/E ratio of -4.26. AURA moved +1.15% today. Year to date, AURA is +44.21%; over the trailing twelve months it is +25.97%. Its 52-week range spans $4.35 to $12.38. Analyst consensus is strong buy with an average price target of $19.75. Rallies surfaces AURA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns AURA stock?

Hedge funds tracked by Rallies that own AURA include Matrix Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Aura Biosciences, Inc. Common Stock.

AURA Key Metrics

Key financial metrics for AURA
Metric	Value
Price	$8.00
Market Cap	$772.30M
P/E Ratio	-4.26
EPS	$-1.76
Dividend Yield	0.00%
52-Week High	$12.38
52-Week Low	$4.35
Volume	444.64K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-106.19M
Gross Margin	0.00%

Top Hedge Funds Holding AURA

Matrix Capital holds 6.92M shares of AURA, changed +0.00% as of Mar 31, 2026.

Latest AURA News

Aura Biosciences Raises $299 Million, Extends Cash Runway into 2H 2028 — May 11, 2026
Aura Biosciences Launches Stock Offering with Pre-Funded Warrants, 15% Overallotment Option — May 4, 2026
Aura Biosciences Raises $144.2M, Expects CoMpass Enrollment by Mid-2026 — Mar 30, 2026
Aura Biosciences Secures FDA SPA for Phase 3 Bel-sar Trial, Expects Mid-Year Bladder Data — Mar 5, 2026
Aura Biosciences’ EPS Estimate Up 5.9%, YTD Return 2.2% — Feb 16, 2026

Recent AURA Insider Trades

Kilroy Conor sold 11.74K (~$82.40K) on Apr 16, 2026.
Kilroy Conor sold 12.08K (~$61.00K) on Feb 17, 2026.
Plavsic Mark sold 15.89K (~$80.24K) on Feb 17, 2026.

AURA Analyst Consensus

5 analysts cover AURA: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.75.

Common questions about AURA

Who owns AURA stock?: Hedge funds tracked by Rallies that own AURA include Matrix Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Aura Biosciences, Inc. Common Stock.
Does Rallies show 13F holders for AURA?: Yes. Rallies tracks hedge fund and 13F ownership data for AURA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is AURA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AURA. It does not provide personalized investment advice.